Results 201 to 210 of about 835,419 (313)

Correction: Tumor organoids may be more suitable for clinical personalized chemotherapeutic drug screening in lung adenocarcinoma. [PDF]

Front Cell Dev Biol
Yun W, Li Y, Ge Y, Zhang X, Liu H, Chen W, Xiao L.   +6 more
europepmc   +1 more source

Development of OTPD4ALS: A Specialized Database for Efficient Screening of Anti-amyotrophic Lateral Sclerosis Drug Candidates

Samuel Oluwaseun Ogunleye, Toheeb Olabisi Adeyeye, Ifeoluwa Elizabeth Aderibigbe, Toluwase Hezekiah Fatoki   +3 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Integrative GWAS and RNA-Seq analysis for target identification and virtual drug screening in colorectal cancer. [PDF]

PLoS One
Liu Q, Lei Y, Liu Z, Han J.
europepmc   +1 more source

Assay Development for High-Throughput Drug Screening Against Mycobacteria [PDF]

Gabriel S. Oliveira, Clara M. Bento, António Pombinho, Rita Santana dos Reis, Kevin Van Calster, Linda De Vooght, André F. Maia, Paul Cos, Maria Salomé Gomes, Tânia Silva   +9 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Retraction Note: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. [PDF]

J Hematol Oncol
Kanojia D, Garg M, Martinez J, M T A, B Luty S, B Doan N, W Said J, Forscher C, W Tyner J, Koeffler HP.   +9 more
europepmc   +1 more source

Drug screening.

Journal of athletic training, 2010
openaire   +1 more source

A Novel Screening Method to Prioritise Cardiovascular Patients Receiving a Pharmaceutical Care Intervention and the Effects on Patients’ Difficulties with Managing Their Drug Treatment

Viktoria Jungreithmayr, Janina A. Bittmann, Viktoria S. Wurmbach, Mónica Degen, Theresa Dierkes, Sofia Obersteiner, Bastian Bruns, S Estel, Till Johannes Bugaj, Hanna M. Seidling   +9 more
openalex   +2 more sources

Machine learning prediction of intestinal α-glucosidase inhibitors using a diverse set of ligands: a drug repurposing effort with drugBank database screening [PDF]

Adeshina I. Odugbemi, Clement Nyirenda, Alan Christoffels, Samuel Egieyeh   +3 more
openalex   +1 more source